Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

Clinical pharmacology and therapeutics - 1 Jun 2004

Wong Mark, Balleine Rosemary L, Collins Michael, Liddle Christopher, Clarke Christine L, Gurney Howard

Abstract excerpt

OBJECTIVES: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analysis of Variance
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Australia

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Linear Models

Share to Metabolic Clearance Rate

Share to Midazolam

Source

Identifiers

PMID: 15179407
DOI: 10.1016/j.clpt.2004.02.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.PMID 15179407Read ↗

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.Semantic proximity Read ↗

Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.Semantic proximity Read ↗

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.Semantic proximity Read ↗

CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.Semantic proximity Read ↗

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.Semantic proximity Read ↗

Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.Semantic proximity Read ↗

Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Semantic proximity Read ↗

The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients.Semantic proximity Read ↗

Factors influencing midazolam hydroxylation activity in human liver microsomes.Semantic proximity Read ↗

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.Semantic proximity Read ↗

Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans.Semantic proximity Read ↗

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.